[Clinical Anslysis of TAFRO Syndrome]
- PMID: 38071075
- DOI: 10.19746/j.cnki.issn.1009-2137.2023.06.042
[Clinical Anslysis of TAFRO Syndrome]
Abstract
Objective: To investigate the clinical characteristics, diagnosis, and treatment of one patient with TAFRO syndrome, and to strengthen the understanding of this rare type.
Methods: The clinical manifestations, diagnosis and treatment process, and prognosis of the patient admitted in Gansu Provincial People's Hospital were retrospectively analyzed.
Results: Combined with laboratory tests, bone marrow examination, imaging, pathology, etc, the patient was diagnosed with TAFRO syndrome. After three cycles of treatment with pomalidomide (2-3 mg/d, d1-21), cyclophosphamide (300 mg/m2, 0.54 g once a week) and dexamethasone (20 mg/d, two days a week), platelet count, serum creatinine and procalcitonin returned to normal, the systemic edema disappeared, and the patient's condition was alleviated. The therapeutic effect was good.
Conclusion: TAFRO syndrome is rare, involves multiple systems, progresses rapidly, and has a worse prognosis. The choice of the "Pomalidomide+cyclophosphamide+dexamethasone" regimen is help to improve the survival prognosis of patient with TAFRO syndrome.
题目: TAFRO综合征临床分析.
目的: 探讨1例TAFRO综合征患者的临床特点及诊疗方案，加强对该类型罕见病的认识.
方法: 回顾性分析甘肃省人民医院收治的1例TAFRO综合征患者的临床表现、诊疗过程及预后.
结果: 结合实验室检查、骨髓学检查、影像学检查及病理学等检查，患者诊断为TAFRO综合征，给予泊马度胺（2-3 mg/d，d 1-21）、环磷酰胺（300 mg/m2，0.54 g每周一次）、地塞米松（20 mg/d，每周两天）方案治疗，3个周期后患者血小板计数、血肌酐、降钙素原等指标均恢复正常，全身水肿消褪，评估病情缓解，治疗效果好.
结论: TAFRO综合征罕见，多系统受累，进展快，预后差，“泊马度胺+环磷酰胺+地塞米松”方案治疗有助于改善TAFRO综合征患者的生存预后.
Keywords: TAFRO syndrome; cyclophosphamide; pomalidomide.